Basic class—schedule II	Proposed year 2007 quotas
Nabilone	2 (
Noroxymorphone (for sale)	1,002
Noroxymorphone (for conversion)	6,600,000
Opium	1,400,000
Oxycodone (for sale)	49,200,000 g
Oxycodone (for conversion)	2,600,000 g
Oxymorphone	1,500,000 g
Pentobarbital	28,000,000 g
Phencyclidine	2,021 g
Phenmetrazine	2 9
Racemethorphan	2 9
Remifentanil	2,700 g
Secobarbital	2 9
Sufentanil	6,500 g
Thebaine	72,453,000 (

The Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations be established at zero.

All interested persons are invited to submit their comments in writing or electronically regarding this proposal following the procedures in the ADDRESSES section of this document. A person may object to or comment on the proposal relating to any of the abovementioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the **Federal Register**, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866.

This action does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this action does not have federalism implications warranting the application of Executive Order 13132.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.* The establishment of aggregate production quotas for

Schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

This action meets the applicable standards set forth in Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.

This action will not result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of \$118,000,000 or more in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

This action is not a major rule as defined by Section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This action will not result in an annual effect on the economy of \$100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

Dated: August 22, 2006.

Michele M. Leonhart,

Deputy Administrator.

[FR Doc. E6–14284 Filed 8–28–06; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF LABOR

Employment and Training Administration

[TA-W-59,772]

E.I. Dupont, Dupont Automotive Systems Division, Troy, MI; Notice of Termination of Investigation

Pursuant to Section 221 of the Trade Act of 1974, as amended, an investigation was initiated on July 25, 2006 in response to a petition filed by a company official on behalf of workers at E.I. DuPont, DuPont Automotive Systems Division, Troy, Michigan. The workers at the subject facility produced automotive paints.

The petitioner has requested that the petition be withdrawn. Consequently, the investigation has been terminated.

Signed in Washington, DC, this 18th day of August, 2006.

Richard Church,

Certifying Officer, Division of Trade Adjustment Assistance.

[FR Doc. E6–14329 Filed 8–28–06; 8:45 am]

DEPARTMENT OF LABOR

Employment and Training Administration

ITA-W-56.672A1

Golden Northwest Aluminum, Inc., Northwest Aluminum Specialties Company, Currently Known as Northwest Aluminum Specialties, Inc., The Dalles, OR; Amended Certification Regarding Eligibility To Apply for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance

In accordance with Section 223 of the Trade Act of 1974 (19 U.S.C. 2273), and Section 246 of the Trade Act of 1974 (26